Because IL-1β is the major effector cytokine produced in gout3 and because NLRP3 inflammasome activation is strongly implicated in the pathogenesis of gout7, repression of the NLRP3 inflammasome could provide an effective therapeutic strategy for gout. This evidence concerns the gene NLRP3 and gout.